Dedicated to improving care

Clinical Research

Elevating Urology Through Clinical Research

Conducting clinical research keeps us at the forefront of urology treatment and gives our patients access to promising treatments and expert knowledge. This research enables us to offer our patients in Philadelphia and surrounding counties the latest advancements in treatments.

Each clinical research trial follows strict guidelines to protect participants. Ask your doctor if there’s a trial that is right for you. Or call our Clinical Research Department at 610-667-0458.

Sponsors and CROs: Learn more about partnering with MidLantic Urology for your next urology trial.

Clinical Trials at MidLantic Urology

Clinical research trials play an essential role in bringing new treatments to our patients. Those who participate in trials enjoy the reassurance and security they get from being closely monitored, and the satisfaction that they are playing an important role in advancing medicine.

These clinical trials are currently available at MidLantic Urology.

Benign Prostatic Hyperplasia

PRODEON - EXPANDER-2 TRIAL

NCT05400980

A Randomized Study to Evaluate the Safety and Efficacy of the Urocross(TM) Expander System and Retrieval Sheath

Learn More

Bladder Cancer

AZ PATAPSCO

NCT05943106

This is an open-label, single-arm, multi-center, Phase IIIb US study exploring the combination of durvalumab and BCG (induction and maintenance) in participants with high-risk NMIBC.

Learn More

JANSSEN BLC3001 - (SUNRISE 2)

NCT04658862

A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy

Learn More

Janssen Moonrise-1

NCT06319820

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

Learn More

JANSSEN SUNRISE-3

NCT05714202

A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical BCG in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer

Learn More

JANSSEN SUNRISE-4

NCT04919512

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)

Learn More

Janssen Sunrise-5

NCT06211764

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (SunRISe-5)

Learn More

JHU J18158

NCT03914794

Phase 2 Window of Opportunity Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients with Recurrent Low- or Intermediate-Risk Tumors

Learn More

Merck 057

NCT02625961

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer

Learn More

MERCK 992

NCT04241185

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

Learn More

MERCK KEYNOTE- 676

NCT03711032

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin in High-Risk Non-Muscle Invasive Bladder Cancer.

Learn More

Seagen

NCT04879329

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Learn More

Interstitial Cystitis

ABBVIE M21-459

NCT05141006

Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

Learn More

Ironwood

NCT05740007

The aim of this study is to assess whether IW-3300 is safe and works for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). The main question the study aims to answer is whether IW-3300 helps bladder pain and other symptoms (for example, bladder burning, pressure and discomfort).

Learn More

Prostate Cancer

ASTRAZENECA – CAPITELLO

NCT04493853

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281)

Learn More

Dendreon Boost

NCT06134232

An Open-Label, Multicenter Study of Subjects With Metastatic Castrate-Resistant Prostate Cancer Treated With PROVENGE® and Boosted With A Single Infusion of Sipuleucel-T to Measure Immune Response

Learn More

Francis Medical - VAPOR 2

NCT05683691

Prospective, Multicenter, Single-Arm Study of VanquishTM Water Vapor Ablation for PrOstate CanceR

Learn More

Janssen 3020

NCT05884398

A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Learn More

MSK: DOCETAXEL & RADIUM -223 (DORA STUDY)

NCT03574571

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer.

Learn More

PROPELLA THERAPEUTICS

NCT04729114

Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Learn More

Urinary Urge Incontinence

Coloplast INTIBIA

NCT05250908

Prospective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).

Learn More

For more information or to enroll in one of these trials, call MidLantic’s Clinical Research Department at 610-667-0458.

A Trusted Team

Clinical trials help scientists better understand disease and develop new medications, treatments, and devices. Our clinical research team is comprised of top physicians and specialists experienced in clinical research. We provide our patients with the opportunity to participate in clinical trials and gain access to the latest therapy and technology available to treat their urologic condition.

Led by Dr. Laurence Belkoff, D.O., F.A.C.O.S and Clinical Research Director Cheryl Zinar, RN, BSN, together oversee a dedicated research team of RNs, Research Assistants and Regulatory Specialists. Backed by a research committee of eight board certified physicians, we continually strive to advance urology health.